1. Guillain-Barré syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study
- Author
-
Peter M Fernandes, Louise Wiblin, Tom Solomon, Jonathan Evans, Benedict D Michael, Bart C Jacobs, Daniel Whittam, Harry Tucker, Emma Tallantyre, David P Breen, Neshika Samarasekera, Kathryn Knight, Martin Zeidler, Julia Stowe, Sonja E Leonhard, Victoria Harris, Helen McDonald, Kathryn Brennan, Eva Maria Hodel, Ralph Gregory, Katy Murray, Simon Shields, Andreas C Themistocleous, Stephen Sawcer, CLARE GALTON, Orla Tuohy, Stephan Hinze, Jacob Roelofs, James Holt, Julian Furby, Bhagteshwar Singh, Lucy Hogg, Scott Ramsay, Shue Jun Cheng, Andrew McHattie, Arina A Tamborska, Taylor Watson-Fargie, Caroline Morrice, Christopher M Allen, Gionathan Amante, Ana Carrilho Romeiro, Ginette Crossingham, Jon Evison, Alifa Isaacs-Itua, Mireia Moragas Garrido, Shelby Ramsamy, Pyae Phyo San, and Robyn Terry
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Objective To investigate features of Guillain-Barré syndrome (GBS) following SARS-CoV-2 vaccines and evaluate for a causal link between the two.Methods We captured cases of GBS after SARS-CoV-2 vaccination through a national, open-access, online surveillance system. For each case, the certainty of GBS was graded using the Brighton criteria, and the relationship to the vaccine was examined using modified WHO Causality Assessment criteria. We compared age distribution of cases with that of prepandemic GBS cases and clinical features with the International GBS Outcome Study (IGOS).Results Between 1 January and 30 June 2021, we received 67 reports of GBS following the ChAdOx1 vaccine (65 first doses) and three reports following the BNT162b2 vaccine (all first doses). The causal association with the vaccine was classified as probable for 56 (80%, all ChAdOx1), possible for 12 (17%, 10 ChAdOx1) and unlikely for two (3%, 1 ChAdOx1). A greater proportion of cases occurred in the 50–59 age group in comparison with prepandemic GBS. Most common clinical variants were sensorimotor GBS (n=55; 79%) and facial diplegia with paraesthesias (n=10; 14%). 10% (n=7/69) of patients reported an antecedent infection, compared with 77% (n=502/652) of the IGOS cohort (p
- Published
- 2022
- Full Text
- View/download PDF